Boost, GPx will refine the accuracy of its debut product, CardioID, the world’s first implant and needle-free remote blood monitoring solution for heart failure patients, while growing revenue, ...
"We are excited to work with the leading heart valve centers in the U.S. to offer more patients suffering from tricuspid regurgitation a treatment option. The initiation of the TANDEM II Early ...
Targeting these specific cells or the signals that drive their transformation, could prevent implant failure for millions of patients who need them, from heart devices to joint replacements.